University of Texas System

Kui Shin Voo

Naoya Tsurushita

J Yun Tso

Shankar Kumar

Yong-Jun Liu

Laura Bover

Bianka Prinz

Dongxing Zha

Michael A Curran

Carlo Toniatti

Ashvin R Jaiswal

Nadthakarn Boland

Eric Krauland

Nga Rewa Houston

The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Human PD-L2 antibodies and methods of use therefor

The present disclosure is directed to antibodies binding to PD-L1 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1.

Human PD-L1 antibodies and methods of use therefor

The present disclosure is directed to dual specificity antibodies which may bind to PD-L1 or PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1 or PD-L2.

Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor

Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

Anti-OX40 antibodies and methods of using the same

Nucleic acid encoding anti-OX40 antibodies

Anti-OX40 antibodies and methods of treating cancer

Growing community of inventors

Pearland, TX, United States of America

Kui Shin Voo